Absci Corp (ABSI)vsVertex Pharmaceuticals Inc (VRTX)
ABSI
Absci Corp
$7.51
-7.97%
HEALTHCARE · Cap: $1.74B
VRTX
Vertex Pharmaceuticals Inc
$515.02
-1.08%
HEALTHCARE · Cap: $137.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 829599% more annual revenue ($12.95B vs $1.56M). VRTX leads profitability with a 30.7% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 58/100 (C).
ABSI
Avoid20
out of 100
Grade: F
VRTX
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.6%
Fair Value
$1.57
Current Price
$7.51
$5.94 premium
Margin of Safety
+46.6%
Fair Value
$974.60
Current Price
$515.02
$459.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 37.8%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 39.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABSI
The strongest argument for ABSI centers on Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.
Bear Case : ABSI
The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, EPS Growth.
Key Dynamics to Monitor
ABSI profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
ABSI carries more volatility with a beta of 2.19 — expect wider price swings.
VRTX is growing revenue faster at 11.8% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (58/100 vs 20/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Absci Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?